Stock Analysis on Net
Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

Total Asset Turnover 
since 2005

Microsoft Excel

Calculation

Pfizer Inc., total asset turnover, long-term trends, calculation

Microsoft Excel
Total asset turnover = Revenues1 ÷ Total assets1
Dec 31, 2024 0.30 = 63,627 ÷ 213,396
Dec 31, 2023 0.26 = 59,553 ÷ 226,501
Dec 31, 2022 0.51 = 101,175 ÷ 197,205
Dec 31, 2021 0.45 = 82,145 ÷ 181,476
Dec 31, 2020 0.28 = 42,678 ÷ 154,229
Dec 31, 2019 0.31 = 51,750 ÷ 167,489
Dec 31, 2018 0.34 = 53,647 ÷ 159,422
Dec 31, 2017 0.31 = 52,546 ÷ 171,797
Dec 31, 2016 0.31 = 52,824 ÷ 171,615
Dec 31, 2015 0.29 = 48,851 ÷ 167,460
Dec 31, 2014 0.29 = 49,605 ÷ 169,274
Dec 31, 2013 0.30 = 51,584 ÷ 172,101
Dec 31, 2012 0.32 = 58,986 ÷ 185,798
Dec 31, 2011 0.36 = 67,425 ÷ 188,002
Dec 31, 2010 0.35 = 67,809 ÷ 195,014
Dec 31, 2009 0.23 = 50,009 ÷ 212,949
Dec 31, 2008 0.43 = 48,296 ÷ 111,148
Dec 31, 2007 0.42 = 48,418 ÷ 115,268
Dec 31, 2006 0.42 = 48,371 ÷ 114,837
Dec 31, 2005 0.44 = 51,298 ÷ 117,565

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1 US$ in millions

The analysis of the financial performance over the reported periods reveals several notable trends in revenues, total assets, and total asset turnover.

Revenues
Revenues displayed fluctuations throughout the years. Initially, revenues remained relatively stable from 2005 to 2009, oscillating around the mid-40,000s to 50,000 US$ million range. A significant rise was observed in 2010, reaching a peak of 67,809 million, followed by generally stable levels through 2014. From 2015 to 2019, revenues hovered around the 51,000-53,000 range, before declining sharply in 2020 to 42,678 million. After 2020, revenues rebounded markedly, reaching a peak of 101,175 million in 2021, suggesting a strong recovery or growth phase. However, this was followed by another sharp decline in 2022 and further moderation in 2023 and 2024, indicating some volatility in recent years.
Total assets
Total assets showed an overall increasing trend across the period, rising from around 117,565 million in 2005 to over 226,501 million by 2023. There was a notable jump between 2008 and 2009, where total assets nearly doubled from approximately 111,148 million to 212,949 million. After this surge, there was a slight downward adjustment until 2014, followed by gradual increases and a renewed rise from 2019 onward, reaching the highest values in the last reported years. The asset growth indicates ongoing investments or acquisitions contributing to the expanded asset base.
Total asset turnover
Total asset turnover, which measures the efficiency of asset use in generating revenues, exhibited a declining trend through most of the early periods. It dropped from 0.44 in 2005 to lows around 0.29 in 2012-2014, reflecting reduced efficiency in asset utilization at that time. There was some improvement between 2015 and 2018, reaching 0.34, before again dipping sharply in 2020 and 2023 with values of 0.28 and 0.26, respectively. A notable increase occurred in 2021 and 2022, when turnover ratios increased to 0.45 and 0.51, suggesting a temporary boost in asset utilization efficiency coinciding with the spike in revenues. However, the turnover values in 2023 and 2024 indicate a reversion to lower efficiency levels.

In summary, the data indicates a company experiencing cycles of growth and contraction in revenues alongside a generally increasing asset base. Efficiency in utilizing assets to generate revenues has seen periods of decline and recovery but appears to exhibit volatility in recent years. The significant increases in assets and revenues during certain years suggest strategic expansions or market opportunities, while recent fluctuations indicate a dynamic operational environment.

Comparison to Competitors

Pfizer Inc., total asset turnover, long-term trends, comparison to competitors

Microsoft Excel
Pfizer Inc. AbbVie Inc. Amgen Inc. Bristol-Myers Squibb Co. Danaher Corp. Eli Lilly & Co. Gilead Sciences Inc. Johnson & Johnson Merck & Co. Inc. Regeneron Pharmaceuticals Inc. Thermo Fisher Scientific Inc. Vertex Pharmaceuticals Inc.
Dec 31, 2024 0.30 0.42 0.35 0.52 0.31 0.57 0.48 0.49 0.55 0.38 0.44 0.49
Dec 31, 2023 0.26 0.40 0.28 0.47 0.28 0.53 0.43 0.51 0.56 0.40 0.43 0.43
Dec 31, 2022 0.51 0.42 0.38 0.48 0.37 0.58 0.43 0.51 0.54 0.42 0.46 0.49
Dec 31, 2021 0.45 0.38 0.40 0.42 0.35 0.58 0.40 0.52 0.46 0.63 0.41 0.56
Dec 31, 2020 0.28 0.30 0.39 0.36 0.29 0.53 0.36 0.47 0.52 0.50 0.47 0.53
Dec 31, 2019 0.31 0.37 0.37 0.20 0.29 0.57 0.36 0.52 0.55 0.53 0.44 0.50
Dec 31, 2018 0.34 0.55 0.34 0.64 0.42 0.56 0.34 0.53 0.51 0.57 0.43 0.49
Dec 31, 2017 0.31 0.40 0.27 0.62 0.39 0.51 0.37 0.49 0.46 0.67 0.37 0.70
Dec 31, 2016 0.31 0.39 0.28 0.58 0.37 0.55 0.53 0.51 0.42 0.70 0.40 0.59
Dec 31, 2015 0.29 0.43 0.29 0.52 0.43 0.56 0.62 0.53 0.39 0.73 0.41 0.41
Dec 31, 2014 0.29 0.72 0.28 0.47 0.54 0.53 0.71 0.57 0.43 0.73 0.39 0.25
Dec 31, 2013 0.30 0.64 0.28 0.42 0.55 0.66 0.48 0.54 0.42 0.71 0.41 0.52
Dec 31, 2012 0.32 0.68 0.31 0.49 0.55 0.66 0.44 0.55 0.45 0.66 0.46 0.55
Dec 31, 2011 0.36 — 0.31 0.64 0.54 0.72 0.47 0.57 0.46 0.34 0.44 0.64
Dec 31, 2010 0.35 — 0.34 0.63 0.59 0.74 0.64 0.60 0.43 0.42 0.51 0.08
Dec 31, 2009 0.23 — 0.36 0.61 0.57 0.80 0.67 0.65 0.24 0.51 0.47 0.05
Dec 31, 2008 0.43 — 0.40 0.70 0.73 0.70 0.72 0.75 0.51 0.36 0.50 0.18
Dec 31, 2007 0.42 — 0.41 0.74 0.63 0.70 0.64 0.75 0.50 0.13 0.46 0.33
Dec 31, 2006 0.42 — 0.41 0.70 0.75 0.71 0.63 0.76 0.51 0.11 0.18 0.23
Dec 31, 2005 0.44 — 0.41 0.68 0.87 0.60 0.48 0.87 0.49 0.16 0.62 0.29

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)

Pfizer Inc., total asset turnover, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)

Microsoft Excel
Pfizer Inc. Pharmaceuticals, Biotechnology & Life Sciences
Dec 31, 2024 0.30 0.43
Dec 31, 2023 0.26 0.40
Dec 31, 2022 0.51 0.47
Dec 31, 2021 0.45 0.45
Dec 31, 2020 0.28 0.39
Dec 31, 2019 0.31 0.39
Dec 31, 2018 0.34 0.45
Dec 31, 2017 0.31 0.40
Dec 31, 2016 0.31 0.41
Dec 31, 2015 0.29 0.42
Dec 31, 2014 0.29 0.44
Dec 31, 2013 0.30 0.43
Dec 31, 2012 0.32 0.45
Dec 31, 2011 0.36 0.47
Dec 31, 2010 0.35 0.47
Dec 31, 2009 0.23 0.39
Dec 31, 2008 0.43 0.57
Dec 31, 2007 0.42 0.56
Dec 31, 2006 0.42 0.54
Dec 31, 2005 0.44 0.57

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

Comparison to Industry (Health Care)

Pfizer Inc., total asset turnover, long-term trends, comparison to industry (health care)

Microsoft Excel
Pfizer Inc. Health Care
Dec 31, 2024 0.30 0.75
Dec 31, 2023 0.26 0.73
Dec 31, 2022 0.51 0.75
Dec 31, 2021 0.45 0.70
Dec 31, 2020 0.28 0.64
Dec 31, 2019 0.31 0.65
Dec 31, 2018 0.34 0.68
Dec 31, 2017 0.31 0.66
Dec 31, 2016 0.31 0.67
Dec 31, 2015 0.29 0.64
Dec 31, 2014 0.29 0.69
Dec 31, 2013 0.30 0.67
Dec 31, 2012 0.32 0.67
Dec 31, 2011 0.36 0.69
Dec 31, 2010 0.35 0.68
Dec 31, 2009 0.23 0.63
Dec 31, 2008 0.43 0.80
Dec 31, 2007 0.42 0.77
Dec 31, 2006 0.42 0.74
Dec 31, 2005 0.44 0.72

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).